Consistent with this observation, our current studies identify MDM2 dependency as a potentially actionable feature of PPM1D-truncated DMGs, leading to genotyping for PPM1D as an inclusion criterion for a clinical trial of an MDM2 inhibitor in pediatric cancers (NCT03654716). This evidence concerns the gene PPM1D and cancer.